Government must act on new hepatitis C meds, says peak body


hepatitis C: bright pink 3D liver in blue body

The Federal Government needs to list new hepatitis C medicines on the PBS without further delay, according to the peak body representing the interests of a quarter of a million Australians living with the liver-destroying virus.

Responding to the latest round of PBAC recommendations, Hepatitis Australia CEO Helen Tyrrell said a total of four groundbreaking curative hepatitis C therapies have now received the green light for inclusion on the PBS but so far no listing date has been confirmed.

“It is a completely unacceptable situation. Recommendations alone will not cure anyone. It’s time to act on the advice of the experts and add these medicines to the PBS,” Tyrrell says.

New anti-viral therapies have exceptionally high cure rates that exceed 90%, shorter treatment durations and avoid the debilitating side-effects associated with existing therapies, she says.

Approximately 230,000 Australians are living with hepatitis C but only 1% are treated each year.

Without urgent access to the new curative treatments, more Australians will progress to serious liver disease, with a 230% increase in the number of deaths due to hepatitis C-related liver disease predicted in the next 15 years.

Tyrrell says that liver clinics are reporting that hundreds of Australians are deferring treatment and waiting anxiously for the PBS listing of new interferon-free medicines.

“Australians living with hepatitis C have already waited too long to access new treatments,” she says. “These medicines need to be made available so people can at last be free of the virus allowing them to resume their productive lives.”

Hepatitis Australia is calling for the Federal Government and pharmaceutical companies to swiftly conclude financial negotiations and put patient lives first, saying that “the cost in human suffering far outweighs monetary considerations”.

Tyrrell said that recent reports of Australians importing generic copies of antiviral medication from overseas highlights the desperation of many people and the need for decisive government action to address growing inequities in treatment access based on the ability to pay.

“Hepatitis Australia notes the Federal Health Minister’s support for our World Hepatitis Day #TimeForAction campaign and we urge her to make these vital medicines available. Further delays are unconscionable,” Tyrrell says.

 

Previous $5 million in grants to Australian research on type 2 diabetes
Next 'A' flagging has Medicines Australia concerned

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.